|
| 新型斑秃治疗药物利特昔替尼的合成进展 |
| Advances in the Synthesis of Ritlecitinib, a Novel Treatment for Alopecia Areata |
| 投稿时间：2025-03-03 修订日期：2025-04-11 |
| DOI： |
| 中文关键词: 利特昔替尼 JAK3/TEC抑制剂 斑秃 合成进展 |
| 英文关键词:Ritlecitinib, JAK3/TEC inhibitor, Alopecia areata, Advances in synthesis |
| 基金项目:陕西省重点研发计划项目（2023-YBNY-249）和杨凌职业技术学院院内基金项目（ZK22-66、SJ2023-005和DT2023-001）资助 |
|
| 摘要点击次数: 9 |
| 全文下载次数: 0 |
| 中文摘要: |
| 利特昔替尼是一种口服的选择性JAK3/TEC激酶抑制剂,由辉瑞公司研发于2023年6月在美国获批上市用于治疗成人和12岁及以上青少年的重度斑秃。本文综述了目前报道的有关利特昔替尼的合成方法研究进展,并讨论了各方法的特点,以期对其工业化生产提供参考。 |
| 英文摘要: |
| Ritelcitinib is an oral selective JAK3/TEC kinase inhibitor developed by Pfizer Inc., which was approved in the United States in June 2023 for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older. This article reviews current research progress on synthetic methods of ritelcitinib reported to date and discusses the characteristics of each approach, aiming to provide insights for its industrial production. |
| 查看/发表评论 下载PDF阅读器 |
| 关闭 |